You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité  dans le document patient supplémentaire Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire.

Displaying Drugs List

2 Items
Other Name(s): Eloxatin®
Funding:
Evidence Building Program
  • Oxaliplatin (EBP) - Colorectal Cancer Patients with Resectable or Potentially Resectable Extrahepatic Metastases
  • Oxaliplatin (EBP) - Supplemental 1
  • Oxaliplatin (EBP) - Supplemental 2
New Drug Funding Program
  • Oxaliplatin and Irinotecan - Advanced Pancreatic Cancer (FOLFIRINOX)
  • Oxaliplatin - Adjuvant Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - With Surgery for Curative Intent for CRC SBAC Pts with Resectable or Potentially Resectable Liver Mets
  • Oxaliplatin - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Nov 2019
Other Name(s): Herceptin®, Ogivri™, Trazimera™, Herzuma®
Funding:
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
  • Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer
Jan 2020